LAB vs LYFT · rev $174.4M vs P/E 108, rev $5.79B
Standard Biotools Inc (LAB) versus LYFT Inc (LYFT) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
LYFT Inc (LYFT) is a software - application company listed on US. It is led by David Risher.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported LYFT revenue for 2024-12-31 was $5.79B. Net income was $22.8M. Revenue was up 31.4% from 2023-12-31 to 2024-12-31. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
LAB currently screens at market cap $317.1M. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
Not investment advice. Open the LAB and LYFT stock pages for the full models.
Not investment advice.